EyePoint, Inc.

EyePoint, Inc. reported a significant widening of its net loss to $179.3 million for the first six months of 2026, compared to $104.6 million in the same period of 2025, while total revenues dropped substantially to $1.2 million from $29.8 million. The company increased its research and development expenses to $155.8 million, reflecting ongoing investment in its pipeline. EyePoint maintains a liquidity position of $180.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months. Key clinical milestones include the anticipated data readout for DURAVYU's wet AMD Phase 3 trials in August 2026 and the completion of enrollment for DME Phase 3 trials in July 2026.

EyePoint, Inc. announced its second quarter 2026 financial results, reporting a net loss of $94.5 million and a significant decrease in total net revenue to $0.5 million. Operating expenses rose to $97.9 million, primarily due to ongoing Phase 3 clinical trials. Despite the financial downturn, the company provided positive updates on its clinical pipeline, with topline data for the LUGANO wet AMD trial expected in August 2026 and full enrollment completed for its DME trials. The company also appointed a new Chief Strategic Science Officer and maintains a cash runway into Q4 2027.

EyePoint, Inc. announced the completion of enrollment for its two pivotal Phase 3 clinical trials, COMO and CAPRI, evaluating DURAVYU™ for the treatment of diabetic macular edema (DME). Over 480 patients were enrolled across both trials in just five months, ahead of schedule. The company anticipates releasing topline 56-week data for these DME trials in the fourth quarter of 2027. An independent Data Safety Monitoring Committee also recommended the continuation of both DURAVYU's wet AMD and DME Phase 3 programs as planned.

EyePoint, Inc. has entered into a settlement agreement with the U.S. Department of Justice and other agencies to resolve potential claims related to alleged civil violations of the False Claims Act. The company will pay a total of $4,678,981.86 plus interest, along with $166,500 for relator's counsel fees, using cash on hand. The settlement addresses sales, marketing, and promotional practices for DEXYCU from 2019 to 2023 and avoids protracted litigation without admitting liability. Additionally, EyePoint entered into a five-year Corporate Integrity Agreement with OIG-HHS, requiring enhanced compliance measures.

EyePoint, Inc. announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer. Dr. Hassan, a globally recognized retina specialist with over 35 years of experience, will join the executive leadership team and provide strategic guidance for the company's pipeline, including DURAVYU™. His appointment comes at a pivotal time as topline data for DURAVYU's Phase 3 wet AMD trials are expected soon. In connection with his hiring, Dr. Hassan received an inducement grant of 100,000 stock options.

EyePoint, Inc. stockholders approved an amendment to the 2023 Long-Term Incentive Plan, increasing the number of shares authorized for issuance by 4,900,000. This approval occurred at the 2026 Annual Meeting, where shareholders also elected eight directors, provided a non-binding advisory approval for named executive officer compensation, and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026.

EyePoint, Inc. announced it granted non-statutory stock options to three new employees as inducement awards. These awards, totaling 39,700 shares, were made outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $12.08 per share and vest over four years, with 25% vesting on the first anniversary and the remainder monthly over the subsequent three years.

EyePoint, Inc. announced that its management will participate in three upcoming healthcare conferences. These include the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Webcasts and replays of the fireside chats will be available on the company's investor website. EyePoint is a clinical-stage biopharmaceutical company focused on retinal diseases, with its lead candidate DURAVYU™ currently in Phase 3 trials for wet AMD and DME, with topline data for wet AMD expected mid-2026.

EyePoint, Inc. announced the grant of non-statutory stock options to eight new employees as inducement awards, outside its 2023 Long-Term Incentive Plan. These options allow the purchase of up to an aggregate of 158,100 shares of EyePoint common stock. The exercise price is $12.35 per share, and the options vest over four years, with 25% on the first anniversary and the remainder in equal monthly installments over the subsequent three years, subject to continued service.

EyePoint, Inc. announced its third consecutive positive recommendation from the independent Data Safety Monitoring Committee (DSMC) for its pivotal Phase 3 program evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD). The DSMC recommended that both the LUGANO and LUCIA trials continue as planned without modifications, reinforcing confidence ahead of topline data expected in mid-2026. The masked safety data from Phase 3 trials continue to show a favorable safety profile, consistent with previous studies involving over 190 patients. All active patients have received their second DURAVYU dose, with over 35% receiving a third dose.